1. Obesity and weight control.
2. Improve blood sugar control in patients with type 2 diabetes.
3. Reduce cardiovascular risk in diabetic patients.
Expanded indications :
The range of indications for semaglutide is constantly expanding, and positive progress has been made in the fields of diabetes complicated with chronic kidney disease, fatty liver, and non-alcoholic steatohepatitis (NASH).
Product Introduction :
Semaglutide oral tablet is the world's first oral GLP-1 receptor agonist drug. The US FDA has granted Breakthrough Therapy Designation to semaglutide for the treatment of nonalcoholic steatohepatitis (NASH).
Semaglutide met its primary endpoint in all four Phase 3 clinical trials in obesity: 16.9%-18.2% weight loss in patients treated with semaglutide at a dose of 2.4 mg. Long-term maintenance: In clinical trials investigating whether semaglutide can maintain weight control in the long term, after 68 weeks of continuous treatment, semaglutide reduced patients' body weight by 18.2%.
Administration and Dosage :
1. Initial dose: 3 mg once a day for 30 days.
2. Dose increase: After 30 days of 3mg dose, increase the dose to daily
Once, 7mg each time.
3. If additional glycemic control is required after at least 30 days at the 7 mg dose, the dose may be increased to 14 mg once daily.